In the BioHarmony Drug Report Database

"Preview" Icon

Tolvaptan

Jynarque, Samsca, Jinarc (tolvaptan) is a small molecule pharmaceutical. Tolvaptan was first approved as Jynarque on 2009-05-19. It is used to treat hyponatremia in the USA. It has been approved in Europe to treat autosomal dominant polycystic kidney and inappropriate adh syndrome. The pharmaceutical is active against vasopressin V2 receptor. In addition, it is known to target vasopressin V1a receptor. Samsca’s patent is valid until 2030-04-07 (FDA).

 

Trade Name

 

Jinarc, Samsca
 

Common Name

 

tolvaptan
 

ChEMBL ID

 

CHEMBL344159
 

Indication

 

autosomal dominant polycystic kidney, hyponatremia, inappropriate adh syndrome
 

Drug Class

 

Vasopressin receptor antagonists

Image (chem structure or protein)

Tolvaptan structure rendering